The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
brain metastases
human epidermal growth factor receptor-2 positive (HER2+)
incidence
metastatic breast cancer
triple negative
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
29
12
2020
medline:
22
6
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2-) MBC; pooled overall estimates for incidence were calculated using random effects models. 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0-34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5-40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9-36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10-0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09-0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03-0.08) for patients with HR+/HER2- MBC. There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.
Sections du résumé
BACKGROUND
Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population.
METHODS
Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2-) MBC; pooled overall estimates for incidence were calculated using random effects models.
RESULTS
937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0-34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5-40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9-36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10-0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09-0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03-0.08) for patients with HR+/HER2- MBC.
CONCLUSION
There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.
Identifiants
pubmed: 33367836
pii: 6046194
doi: 10.1093/neuonc/noaa285
pmc: PMC8168821
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
894-904Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
BMC Cancer. 2009 Oct 17;9:367
pubmed: 19835621
J Clin Oncol. 2015 May 10;33(14):1564-73
pubmed: 25605838
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
Clin Cancer Res. 2011 Jul 15;17(14):4834-43
pubmed: 21768129
Breast Cancer Res Treat. 2019 Jan;173(1):225-237
pubmed: 30293212
J Cancer Res Clin Oncol. 2018 Sep;144(9):1803-1816
pubmed: 29971531
Acta Oncol. 2006;45(2):196-201
pubmed: 16546866
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Breast Care (Basel). 2014 Oct;9(5):344-8
pubmed: 25759615
J Clin Oncol. 2000 Jun;18(11):2349-51
pubmed: 10829059
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
Oncotarget. 2019 Oct 29;10(59):6317-6322
pubmed: 31695840
JAMA Oncol. 2016 Dec 1;2(12):1557-1564
pubmed: 27078022
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Cancer Causes Control. 2012 Jan;23(1):103-12
pubmed: 22037907
Acta Clin Belg. 2014 Jun;69(3):194-9
pubmed: 24641516
Clin Breast Cancer. 2018 Apr;18(2):e187-e195
pubmed: 28888580
J Clin Oncol. 2006 Dec 20;24(36):5658-63
pubmed: 17102066
Br J Cancer. 2019 Dec;121(12):991-1000
pubmed: 31719684
Ann Oncol. 2020 Oct;31(10):1350-1358
pubmed: 32634611
Clin Breast Cancer. 2020 Feb;20(1):e54-e64
pubmed: 31447286
Onkologie. 2011;34(6):304-8
pubmed: 21625183
JAMA Oncol. 2017 Aug 1;3(8):1069-1077
pubmed: 28301662
Ann Oncol. 2011 Jul;22(7):1571-1581
pubmed: 21059640
JAMA Oncol. 2018 Jul 1;4(7):1001-1003
pubmed: 29799956
Nat Med. 2020 Aug;26(8):1280-1284
pubmed: 32483359
Front Psychol. 2015 Oct 08;6:1549
pubmed: 26500598
Clin Pharmacol Ther. 2010 May;87(5):586-92
pubmed: 20357763
J Cancer Epidemiol. 2012;2012:819210
pubmed: 22570657
Int J Clin Oncol. 2009 Feb;14(1):48-52
pubmed: 19225924
Breast Cancer Res Treat. 2005 Jun;91(3):217-25
pubmed: 15952055
Clin Oncol (R Coll Radiol). 2015 Aug;27(8):460-4
pubmed: 25976296
Cancer. 2005 Feb 1;103(3):442-3
pubmed: 15578684
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Clin Breast Cancer. 2003 Jun;4(2):114-9
pubmed: 12864939
BMC Cancer. 2018 Apr 19;18(1):446
pubmed: 29673325
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
Anticancer Res. 2007 Jul-Aug;27(4C):2865-9
pubmed: 17695462
Eur J Cancer. 2004 Feb;40(3):379-82
pubmed: 14746856
Cancer. 2004 Aug 15;101(4):810-6
pubmed: 15305414
Chin Med J (Engl). 2013 Apr;126(7):1269-75
pubmed: 23557557
Tumour Biol. 2013 Oct;34(5):3153-8
pubmed: 23729232
Ann Oncol. 2014 Jun;25(6):1116-21
pubmed: 24685829
Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80
pubmed: 18379783
Breast. 2014 Oct;23(5):623-8
pubmed: 24993072
Sci Rep. 2018 Jul 17;8(1):10784
pubmed: 30018387
Br J Cancer. 2004 Aug 16;91(4):639-43
pubmed: 15266327
Ann Oncol. 2015 Jan;26(1):113-119
pubmed: 25355722
Breast Cancer Res Treat. 2012 Nov;136(1):153-60
pubmed: 22968656
JCO Precis Oncol. 2020 May 27;4:
pubmed: 32923889
Cancer. 2003 Jun 15;97(12):2972-7
pubmed: 12784331
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2065-71
pubmed: 21596487
PLoS One. 2014 Feb 24;9(2):e89389
pubmed: 24586742
Oncologist. 2007 Jul;12(7):766-73
pubmed: 17673608